ExThera Medical Announces Completion of CE Mark Registration Trial Evaluating the Safety of Seraph® 100 Blood Filter
ExThera Medical Corporation, a developer of therapies for removing bacteria and viruses from blood, today announced that it completed its CE Mark registration trial evaluating the safety of the Seraph® 100 Microbind® Affinity Blood Filter (Seraph) in renal replacement therapy patients who developed bacteremia. The prospective, non-randomized study enrolled 15 patients across four trial sites in Germany and the final follow-up day for the last patient enrolled in the trial was June 7, 2018. ExThera Medical expects to move forward with the regulatory submission of CE Mark data in the European Union (EU) in the fourth quarter of 2018.
“The completion of the European trial represents an exciting step forward in our effort to make a simple, device-based treatment like Seraph, available for bloodstream infections,” said Bob Ward, CEO, ExThera Medical. “With the lack of effective antibiotics for many bloodstream infections and limited new anti-infectives in development, there is a significant unmet need for new approaches that can help treat drug-resistant infections, especially in patients at high risk like those undergoing dialysis.”
The primary outcome measure of the study is to demonstrate the safety of Seraph in a hemodialysis circuit assessed by rate of adverse events (time frame: 14 days). The secondary outcome measure is the reduction of bacteria in blood passed through the Seraph filter (time frame: 4 hours). In the study, patients on renal replacement therapy who developed bacteremia had the Seraph filter included in the dialysis circuit for 4 hours, with hourly monitoring. Patients were monitored for 14 days following treatment.
Interim safety and performance data from the trial was presented on March 20, 2018 at the International Symposium on Intensive Care and Emergency Medicine Congress in Brussels and showed that Seraph appears to be safe and effective, and compatible with widely-used dialysis equipment and procedures. Final results from the trial are currently being analyzed and are expected to be available in October 2018. To date, there have been no device or treatment related adverse events reported during the trial.
“Our preclinical studies and the interim data from this study suggest that Seraph is well tolerated when used during dialysis as a treatment to quickly reduce the level of blood-borne pathogens in bacteremia patients,” said Kathleen White, VP and COO, ExThera Medical. “We look forward to analyzing the complete study results as we continue our work on making this novel device, that uses biomimetic adsorption media to treat bloodstream infections, available in Europe.”
The U.S. Food and Drug Administration granted Seraph inclusion in its Expedited Access Pathway (EAP) program. EAP designation is granted to devices that have the potential to satisfy unmet clinical needs in the prevention of fatal or debilitating diseases.
About the Seraph ® Microbind ® Affinity Blood Filter
As a patient's blood flows through the Seraph Microbind Affinity Blood Filter, it passes over proprietary microspheres coated with molecular receptor sites that mimic the receptors on human cells that pathogens use when they invade the body. Harmful substances are quickly captured and adsorbed onto the proprietary surface and are thereby removed from the bloodstream without adding anything to the blood, which is returned to the patient with blood cells intact. The adsorption media is a flexible platform using chemically-bound, immobilized heparin for its blood compatibility, and its unique binding capacity for pathogens.
Seraph may be configured with optional supplemental adsorbents to remove other toxins and evolved pathogens. For example, ‘Seraph 200’ adds endotoxin binding to Seraph 100, which may be useful in certain bloodstream infections that progress to endotoxemia. The Seraph filters have a blood-contacting surface that is anti-thrombogenic and anti-inflammatory.
About ExThera Medical
Based in Martinez, Calif., ExThera Medical is a privately held medical device company developing innovative, single-use blood filters capable of capturing and removing a broad range of bacteria, viruses, parasites, toxins or other harmful substances from whole blood. The company develops therapeutic products to treat patients in the hospital or clinic, or on the battlefield. Led by an accomplished management team with extensive experience in blood-contacting devices and biomaterials, the company has strong patent protection and a growing body of data from independent laboratory studies, in addition to its participation in DARPA’s Dialysis-Like Therapeutics program. For more information, visit www.extheramedical.com .
Disclaimer : All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.
Caution : The Seraph® Microbind® Affinity Blood Filter is currently undergoing clinical evaluation and is not available for commercial sale.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
MYPOS-EUROPE-LTD23.10.2018 18:24 | pressemeddelelse
myPOS Founder Christo Georgiev Announces Two Upcoming myPOS Stores in Barcelona and Paris
MYPOS23.10.2018 18:13 | pressemeddelelse
Christo Georgiev Announces the Arrival of myPOS AppMarket
CNIM23.10.2018 17:47 | pressemeddelelse
CNIM Presents a Rapid Version of The LCAT® Shore-to-Shore Featuring Unique Operational Capabilities
FL-H.I.G.-CAPITAL23.10.2018 15:05 | pressemeddelelse
Exterior Plus, a Portfolio Company of H.I.G. Capital, Acquires Impactmedia
CA-VISA-INC.23.10.2018 15:02 | pressemeddelelse
Visa Brings a Simpler, Safer Experience to Digital Payments
TX-ACTIVE-SEMI23.10.2018 15:02 | pressemeddelelse
Active-Semi’s New PMICs Reduce Size and Increase Power Density with Leading Field Programable Technology
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum